Oral tiludronate: pharmacological properties and potential usefulness in Paget's disease of bone and osteoporosis.
Reginster
J Y
JY
Bone Metabolism Unit, University of Liege, Belgium.
D000818:Animals; D001851:Bone Diseases, Metabolic / Q000188:drug therapy*; D001862:Bone Resorption / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004164:Diphosphonates / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D004285:Dogs; D004341:Drug Evaluation; D004361:Drug Tolerance; D005260:Female; D006801:Humans; D008297:Male; D051379:Mice; D010001:Osteitis Deformans / Q000188:drug therapy*; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy*; D010215:Papio; D051381:Rats; D014018:Tissue Distribution
D004164:Diphosphonates; C058651:tiludronic acid